ES2108455T3 - Ensayo en celulas para diagnosticar la enfermedad de alzheimer. - Google Patents

Ensayo en celulas para diagnosticar la enfermedad de alzheimer.

Info

Publication number
ES2108455T3
ES2108455T3 ES94915953T ES94915953T ES2108455T3 ES 2108455 T3 ES2108455 T3 ES 2108455T3 ES 94915953 T ES94915953 T ES 94915953T ES 94915953 T ES94915953 T ES 94915953T ES 2108455 T3 ES2108455 T3 ES 2108455T3
Authority
ES
Spain
Prior art keywords
disease
alzheimer
cell test
diagnose alzheimer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915953T
Other languages
English (en)
Inventor
Daniel L Alkon
Rene Etcheberrigaray
Ito Etsuro
Gary E Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
US Department of Health and Human Services
Original Assignee
Cornell Research Foundation Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc, US Department of Health and Human Services filed Critical Cornell Research Foundation Inc
Application granted granted Critical
Publication of ES2108455T3 publication Critical patent/ES2108455T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION ES UN METODO PARA EL DIAGNOSTICO DE LA ENFERMEDAD DE ALZHEIMER UTILIZANDO CELULAS HUMANAS ESPECIFICAMENTE, EL METODO DETECTA DIFERENCIAS ENTRE LOS CANALES DE POTASIO EN CELULAS DE UN PACIENTE CON ALZHEIMER Y DONANTES NORMALES, Y LAS DIFERENCIAS EN CONCENTRACIONES DE CALCIO INTRACELULARES ENTRE CELULAS NORMALES Y CELULAS DE ALZHEIMER EN RESPUESTA A SUSTANCIAS QUIMICAS CONOCIDAS POR INCREMENTAR LOS NIVELES DE CALCIO INTRACELULAR.
ES94915953T 1993-05-03 1994-05-02 Ensayo en celulas para diagnosticar la enfermedad de alzheimer. Expired - Lifetime ES2108455T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/056,456 US5580748A (en) 1993-05-03 1993-05-03 Diagnostic tests for alzheimers disease

Publications (1)

Publication Number Publication Date
ES2108455T3 true ES2108455T3 (es) 1997-12-16

Family

ID=22004526

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915953T Expired - Lifetime ES2108455T3 (es) 1993-05-03 1994-05-02 Ensayo en celulas para diagnosticar la enfermedad de alzheimer.

Country Status (11)

Country Link
US (1) US5580748A (es)
EP (1) EP0697111B1 (es)
JP (1) JPH09500202A (es)
AT (1) ATE155888T1 (es)
AU (1) AU689776B2 (es)
CA (1) CA2162048A1 (es)
DE (1) DE69404460T2 (es)
DK (1) DK0697111T3 (es)
ES (1) ES2108455T3 (es)
GR (1) GR3025126T3 (es)
WO (1) WO1994025872A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
US5902732A (en) * 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US6573063B2 (en) * 1995-10-04 2003-06-03 Cytoscan Sciences, Llc Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
US6183975B1 (en) * 1997-02-24 2001-02-06 J. Jay Gargus Method of detection of congenital disease
AU750582B2 (en) * 1997-11-10 2002-07-25 Bristol-Myers Squibb Company Method for diagnosing Alzheimer's disease
US6087118A (en) * 1999-03-04 2000-07-11 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
US6596474B1 (en) 1999-07-01 2003-07-22 Scios Inc. Prevention and treatment of amyloid-associated disorders
WO2001077686A2 (en) * 2000-04-05 2001-10-18 Neurologic, Inc. Cellular calcium responce for diagnosis of alzheimer's disease
US6495335B2 (en) * 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
GB0107231D0 (en) 2001-03-22 2001-05-16 Imp College Innovations Ltd Patch clamp
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US20070054890A1 (en) * 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
RU2008115455A (ru) * 2005-11-03 2009-12-10 Рэдпойнт Био Корпорэйшн (Us) Высокопроизводительный скрининг-анализ ионного канала trpm5
CA2659242C (en) 2006-07-28 2015-08-11 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
KR20140049054A (ko) * 2007-02-09 2014-04-24 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 두부 외상으로 유발된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과
CL2007002908A1 (es) * 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
EP2483684B1 (en) * 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Fibroblast growth patterns to diagnose alzheimer's disease
US20160186263A1 (en) 2013-05-09 2016-06-30 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
CN106030310B (zh) 2013-12-13 2019-01-04 通用医疗公司 可溶性高分子量(hmw)tau种类及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
JPH03505868A (ja) * 1988-04-08 1991-12-19 マサチユセツツ・インスチチユート・オブ・テクノロジー 神経性疾患を治療するための方法及び組成物

Also Published As

Publication number Publication date
AU6778494A (en) 1994-11-21
WO1994025872A1 (en) 1994-11-10
EP0697111A1 (en) 1996-02-21
ATE155888T1 (de) 1997-08-15
HK1001500A1 (en) 1998-06-19
CA2162048A1 (en) 1994-11-10
AU689776B2 (en) 1998-04-09
DE69404460D1 (de) 1997-09-04
EP0697111B1 (en) 1997-07-23
DE69404460T2 (de) 1998-02-26
DK0697111T3 (da) 1998-03-02
JPH09500202A (ja) 1997-01-07
US5580748A (en) 1996-12-03
GR3025126T3 (en) 1998-02-27

Similar Documents

Publication Publication Date Title
DE69404460D1 (de) Zell-test für alzheimersche krankheit
ATE235057T1 (de) Cell test und diagnostischer kit für alzheimer- erkrankung
WO1999058981A3 (en) Diagnostic tests for alzheimer's disease
WO2000066762A3 (en) Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
ATE325343T1 (de) Diagnose und behandlung von arthritischen erkrankungen
ATE155811T1 (de) Menschliche cyclooxygenase-2cdna und bestimmung von menschliche cyclooxygenase-2-inhibierung
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
ES2151880T3 (es) Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
ES2148967T3 (es) Sustancias y metodos destinados al diagnostico y al tratamiento de la pre-eclampsia.
DK1016056T3 (da) Demostrationsindretning af form som et levende væsen
PT841939E (pt) Agentes terapeuticos e doencas auto-imunes
BR0009771A (pt) Utilização de derivados de bisindóis indigóides capazes de penetrarem na membrana de células
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
EP0783524A4 (en) PEPTIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NO986218L (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100
Seller et al. Magnesium metabolism in hypertension
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
BR9908443A (pt) Linhagens de células de medula espinhal humana e métodos para uso das mesmas
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
Petitti et al. Physiologic measures in men with and without vasectomies

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 697111

Country of ref document: ES